DHR vs RGEN vs TECH Stock Comparison

Danaher, Repligen and Bio-Techne Prices as of Nov 13, 2026 Peers: Industry group
DHR Danaher Corp /De/
$233.03 +3.7% 1M +5.3% 1Y
Market cap
$163.59B
P/E
37.8x
Revenue (TTM)
$25.61B
Div. yield
–
Life Sciences Tools Healthcare
6 wins
RGEN Repligen Corp
$167.79 -5.8% 1M +11.4% 1Y
Market cap
$9.37B
P/E
–
Revenue (TTM)
$805.61M
Div. yield
–
Life Sciences Tools Healthcare
2 wins
TECH BIO-TECHNE Corp
$72.80 +0.4% 1M +19.8% 1Y
Market cap
$11.42B
P/E
66.4x
Revenue (TTM)
$1.23B
Div. yield
0.00%
Life Sciences Tools Healthcare
3 wins

Head to Head

11 decided of 12

Danaher leads on 6 of the 12 questions below (Danaher 6, Bio-Techne 3, Repligen 2). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionDHRRGENTECHLeader
Larger companyMarket capitalisation $163.59B $9.37B $11.42B DHR
Cheaper on earningsLower P/E, profitable companies only 37.8x -793.7x 66.4x DHR
Cheaper on forward earningsLower price / next fiscal year consensus EPS 25.6x 86.0x 33.4x DHR
Faster revenue growthRevenue growth, trailing twelve months +5.5% +13.8% +0.9% RGEN
More profitableNet margin, trailing twelve months 16.9% -1.5% 14.0% DHR
Better return on capitalReturn on invested capital 5.8% 0.0% 7.8% TECH
Less leveragedLower net debt / EBITDA 2.6x -2.8x -0.4x RGEN
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +5.3% +11.4% +19.8% TECH
Better 5-year returnAnnualised price return, 5 years -5.2%/yr -8.3%/yr -10.4%/yr DHR
Less volatileAnnualised volatility, 1 year 31.0% 46.5% 42.8% DHR
Higher overall scoreMean of the five percentile scores vs peers 60/100 58/100 68/100 TECH

Percentile Scorecard

DHRRGENTECH

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisDHRRGENTECH
Valuation 69 #76 of 243 56 #108 of 243 62 #92 of 243
Growth 25 #172 of 228 30 #161 of 228 56 #102 of 228
Profitability 86 #32 of 222 67 #75 of 222 94 #15 of 222
Financial Health 47 #133 of 248 80 #50 of 248 79 #53 of 248
Shareholder Returns 73 #44 of 158 57 #68 of 158 47 #84 of 158
Overall 60 58 68
  • DHR ranked among 252 companies in Medical Devices and Diagnostics
  • RGEN ranked among 252 companies in Medical Devices and Diagnostics
  • TECH ranked among 252 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodDHRRGENTECHSPY
1 month +3.7%-5.8%+0.4% -2.0%
3 months +15.1%+0.6%+0.6% -2.8%
6 months +43.9%+63.1%+68.1% +2.0%
Year to date +1.8%+2.4%+23.8% +10.6%
1 year +5.3%+11.4%+19.8% +12.2%
3 years +14.5%+9.1%+20.6% +68.1%
3 years, per year +4.6%+2.9%+6.5% +18.9%
5 years -23.4%-35.1%-42.3% +61.4%
5 years, per year -5.2%-8.3%-10.4% +10.1%
10 years +187.9%+419.6%+173.4% +248.5%
10 years, per year +11.2%+17.9%+10.6% +13.3%

Risk

MeasureDHRRGENTECHSPY
Volatility, 1Y 31.0%46.5%42.8% 13.6%
Downside volatility, 1Y 32.4%47.4%43.2% 13.9%
Beta vs S&P 500, 1Y 0.551.210.63 1.00
Return / volatility, 1Y 0.170.250.46 0.90
Max drawdown, 5Y -50.8%-64.7%-66.5% -25.4%
From 52-week high -3.7%-13.8%-0.1% -3.2%
52-week high $242.05$194.57$72.84 $779.14
52-week low $161.91$102.87$43.30 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleDHRRGENTECH
P/E now vs peer median 37.9xmedian 26.5x -804.0xmedian 26.5x 66.4xmedian 26.5x
P/S now vs peer median 6.4xmedian 2.7x 11.8xmedian 2.7x 9.3xmedian 2.7x
EV/EBITDA now vs peer median 23.5xmedian 18.4x 83.9xmedian 18.4x 33.4xmedian 18.4x
P/FCF now vs peer median 28.6xmedian 25.4x 89.1xmedian 25.4x 37.1xmedian 25.4x
P/B now vs peer median 3.1xmedian 2.5x 4.5xmedian 2.5x 5.3xmedian 2.5x
PEG now vs peer median -4.72median 0.98 28.28median 0.98 -6.27median 0.98

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsDHRRGENTECH
Revenue $25.61B $805.61M $1.23B
Gross profit $15.01B $430.67M $807.58M
Operating income $5.22B $18.24M $240.84M
Net income $4.33B -$11.80M $171.97M
Free cash flow $5.73B $106.72M $308.20M
R&D $1.67B $57.23M $96.87M
EPS (diluted) $6.13 $-0.21 $1.09
Cash & equivalents $5.68B $726.96M $350.04M
Total debt $26.48B $555.60M $200.00M
Shares (diluted) 706.80M 56.56M 157.93M
Enterprise value $143.24B $6.14B $10.42B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricDHRRGENTECH
P/E 37.9x -804.0x 66.4x
P/FCF 28.6x 89.1x 37.1x
P/Operating cash flow 23.9x 73.2x 33.9x
P/S 6.4x 11.8x 9.3x
P/B 3.1x 4.5x 5.3x
P/Tangible book 5.0x 5.3x 6.1x
EV/EBITDA 23.5x 83.9x 33.4x
EV/EBIT 35.4x 504.7x 46.9x
EV/Revenue 7.2x 11.4x 9.2x
EV/FCF 32.3x 86.3x 36.6x
EV/Operating cash flow 26.9x 70.9x 33.4x
PEG (3Y EPS CAGR) -4.72 28.28 -6.27

Growth

14 metrics
MetricDHRRGENTECH
Revenue growth (1Y) 5.5% 13.8% 0.9%
Revenue CAGR (3Y) 1.3% 7.3% 2.4%
Gross profit growth (1Y) 3.9% 33.0% 1.5%
Gross profit CAGR (3Y) 1.2% 13.3% 1.4%
Operating income growth (1Y) 13.1% 2,185% 119.1%
Operating income CAGR (3Y) -3.8% -40.5% -6.9%
Net income growth (1Y) 23.6% -779.2% 120.5%
Net income CAGR (3Y) -9.9% -28.4% -11.3%
EPS growth (1Y) 24.8% -778.9% 118.3%
EPS CAGR (3Y) -8.0% -28.4% -10.6%
Operating cash flow growth (1Y) 8.6% -0.8% 34.4%
Operating cash flow CAGR (3Y) -5.3% 5.3% 9.4%
Free cash flow growth (1Y) 14.2% -3.0% 37.6%
Free cash flow CAGR (3Y) -5.8% 17.6% 12.7%

Profitability

14 metrics
MetricDHRRGENTECH
Gross margin 58.6% 53.5% 65.8%
EBITDA margin 30.7% 13.6% 27.5%
Operating margin 20.4% 2.3% 19.6%
Pretax margin 18.8% 1.0% 18.5%
Net margin 16.9% -1.5% 14.0%
FCF margin 22.4% 13.2% 25.1%
Operating cash flow margin 26.8% 16.1% 27.5%
Return on equity 8.2% -1.7% 7.7%
Return on assets 4.7% -1.2% 6.3%
Return on invested capital 5.8% 0.0% 7.8%
Return on capital employed 6.2% 0.6% 10.7%
Asset turnover 0.3x 0.3x 0.5x
Cash conversion (OCF / net income) 1.6x -11.0x 2.0x
Stock comp / revenue 1.3% 4.2% 1.6%

Financial Health

11 metrics
MetricDHRRGENTECH
Debt / assets 28.4% 19.0% 7.6%
Debt / equity 0.5x 0.3x 0.1x
Net debt / EBITDA 2.6x -2.8x -0.4x
Debt / FCF 4.6x 5.2x 0.6x
Liabilities / assets 42.5% 28.5% 17.9%
Equity / assets 57.5% 71.5% 82.1%
Interest coverage 14.5x 0.8x 27.2x
Current ratio 1.6x 9.9x 2.3x
Quick ratio 1.1x 8.1x 1.5x
Cash ratio 0.6x 6.9x 1.0x
Altman Z-score 3.75 7.80 16.15

Shareholder Returns

7 metrics
MetricDHRRGENTECH
Dividend yield 0.7% – 0.5%
Net buyback yield 0.5% -0.2% -0.5%
Shareholder yield 1.1% -0.2% 0.1%
Payout ratio (earnings) – – 29.1%
Payout ratio (FCF) – – 16.2%
Dividend growth (1Y) – – -0.2%
Dividend CAGR (3Y) – – -0.2%

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusDHRRGENTECH
Forward P/E 25.6xFY2026 86.0xFY2026 33.4xFY2027
EPS, next fiscal year $9.12FY2026 $1.95FY2026 $2.18FY2027
EPS growth, next FY +16.9%FY2026 +14.0%FY2026 +13.0%FY2027
EPS growth, the year after +7.9% +29.2% +3.2%
Revenue, next fiscal year $27.01BFY2026 $791.31MFY2026 $1.19BFY2027
Revenue growth, next FY +9.9%FY2026 +7.2%FY2026 -2.1%FY2027
Revenue growth, the year after -1.9% +44.3% +13.5%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersDHRRGENTECH
Held by institutions 81.9% 100.0% 100.0%
Institutions holding 2,121 483 599
Change in shares held, QoQ +1.1% +1.2% -0.6%
Institutions buying 841 273 293
Institutions selling 1,016 141 241
Buyers to sellers 0.83 1.94 1.22

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

DHRRGENTECH
DHR 1.00 0.64 0.38
RGEN 0.64 1.00 0.44
TECH 0.38 0.44 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, DHR, RGEN and TECH?

Danaher (DHR) is the largest by market capitalisation: Danaher (DHR) $163.59B, Repligen (RGEN) $9.37B, Bio-Techne (TECH) $11.42B.

Which stock is cheaper, DHR, RGEN and TECH?

Danaher (DHR) trades on the lowest price-to-earnings ratio (Danaher (DHR) 37.8x, Repligen (RGEN) -793.7x, Bio-Techne (TECH) 66.4x). On next year's consensus earnings, Danaher (DHR) is cheapest (Danaher (DHR) 25.6x, Repligen (RGEN) 86.0x, Bio-Techne (TECH) 33.4x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Repligen (RGEN) grew revenue fastest over the trailing twelve months: Danaher (DHR) +5.5%, Repligen (RGEN) +13.8%, Bio-Techne (TECH) +0.9%.

Which company is more profitable?

Danaher (DHR) has the highest net margin (Danaher (DHR) 16.9%, Repligen (RGEN) -1.5%, Bio-Techne (TECH) 14.0%). On return on invested capital, Bio-Techne (TECH) leads (Danaher (DHR) 5.8%, Repligen (RGEN) 0.0%, Bio-Techne (TECH) 7.8%).

Which stock has performed better?

Over the past year Bio-Techne (TECH) returned the most: Danaher (DHR) +5.3%, Repligen (RGEN) +11.4%, Bio-Techne (TECH) +19.8%. Over five years, Danaher (DHR) compounded fastest (Danaher (DHR) -5.2%/yr, Repligen (RGEN) -8.3%/yr, Bio-Techne (TECH) -10.4%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: Danaher (DHR) 0.00%, Repligen (RGEN) 0.00%, Bio-Techne (TECH) 0.00%. Danaher (DHR) and Repligen (RGEN) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Danaher (DHR) has been the steadiest (Danaher (DHR) 31.0%, Repligen (RGEN) 46.5%, Bio-Techne (TECH) 42.8%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, DHR, RGEN and TECH?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Danaher (DHR) leads on 6. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.